Search Weight Loss Topics:




Aug 21

Ascendis Pharma A/S American (NASDAQ:ASND) Sees Heavy Trading Volume with 107K Shares Changing Hands – Modern Readers

Advertisement

Trading was heavy with 107K shares changing hands by the end of trading on Tuesday. Volume was up 156.20% over the stocks average daily volume.

Here are a few other firms who have also updated their positions. As of the end of the quarter Tower Research Capital LLC (trc) had disposed of 1,133 shares trimming its position 100.0%. The value of the investment in Ascendis Pharma A/S American decreased from $32,000 to $0 a change of 100.0% quarter to quarter. As of quarter end Vhcp Management Ii, LLC had bought a total of 175,000 shares growing its holdings by 21.6%. The value of the investment in (ASND) went from $22,722,000 to $27,385,000 a change of $4,663,000 quarter over quarter.

As of the end of the quarter Morgan Stanley had acquired a total of 1,553 shares growing its stake by 103.7%. The value of the investment in ASND went from $42,000 to $85,000 increasing 102.4% since the last quarter. As of the end of the quarter Wells Fargo & Company/mn had sold 1,716 shares trimming its holdings by 33.6%. The value of the total investment in Ascendis Pharma A/S American decreased from $143,000 to $94,000 a change of 34.3% for the reporting period.

On May 11 analysts at JP Morgan began coverage giving it an initial rating of Overweight.

The company is now down since yesterdays close of $27.9.

Ascendis Pharma A/S, launched on September 21, 2006, is a clinical-stage biopharmaceutical company. The Company is involved in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism. The Businesss subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark) and Ascendis Pharma Growth Disorders A/S (Denmark)..

Excerpt from:
Ascendis Pharma A/S American (NASDAQ:ASND) Sees Heavy Trading Volume with 107K Shares Changing Hands - Modern Readers

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)
Select Your US State
Program Choice
Confirm over 30 years old Yes
Confirm that you resident in USA Yes
This is a Serious Inquiry Yes
Message:
captcha


Related Post